You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Chimeric antigen receptor (CAR)

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoid Leukemia Trial in Palo Alto (Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector

Not yet recruiting
  • Lymphoid Leukemia
  • Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)
  • Treg CD34+ HSPC (Orca-T)
  • Palo Alto, California
    Stanford Cancer Center
Aug 17, 2022

Acute Lymphoid Leukemia, B-Cell Leukemia, Leukemia, Lymphocytic, B Cell Trial run by the National Cancer Institute (NCI)

Not yet recruiting
  • Acute Lymphoid Leukemia
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

Tumors, Hematologic Tumors, Hematologic Diseases Trial in Xuzhou (RD13-02 cell infusion)

Recruiting
  • Neoplasms
  • +2 more
  • RD13-02 cell infusion
  • Xuzhou, Jiangsu, China
    Affiliated hospital of Xuzhou medical college
Jun 7, 2023

Diffuse Large B Cell Lymphoma Trial in Tampa (Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Itacitinib
  • Chimeric antigen receptor (CAR) T-cell therapy
  • Tampa, Florida
    Moffitt Cancer Center
Mar 6, 2023

Platinum-Resistant Ovarian Carcinoma Trial in Duarte (Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine)

Recruiting
  • Platinum-Resistant Ovarian Carcinoma
  • Chimeric Antigen Receptor T-cells
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Jul 21, 2022

Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL Trial in Calgary, Edmonton (autologous CD19-directed

Recruiting
  • Relapsed Non Hodgkin Lymphoma
  • +2 more
  • autologous CD19-directed chimeric antigen receptor (CAR) T-cells
  • Calgary, Alberta, Canada
  • +5 more
Jul 18, 2022

Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,

Recruiting
  • Lupus Nephritis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Denver, Colorado
  • +1 more
Jul 7, 2023

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

Not yet recruiting
  • Multiple Sclerosis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Palo Alto, California
    Stanford Multiple Sclerosis Center
Nov 13, 2023

Recurrent Glioblastoma Trial (Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T

Not yet recruiting
  • Recurrent Glioblastoma
  • Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection
  • (no location specified)
Apr 4, 2023

Gastric Cancer, Colon Cancer, Rectal Cancer Trial in Taiyuan (CEA-targeted CAR-T cells)

Recruiting
  • Gastric Cancer
  • +6 more
  • CEA-targeted CAR-T cells
  • Taiyuan, Shanxi, China
  • +1 more
Aug 24, 2023

Germ Cell Tumor, Nonseminomatous Germ Cell Tumor Trial in Chapel Hill (ATLCAR.CD30 Cells, Cyclophosphamid, Fludarabine)

Recruiting
  • Germ Cell Tumor
  • Nonseminomatous Germ Cell Tumor
  • ATLCAR.CD30 Cells
  • +2 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Dec 13, 2022

CNS Tumor, Pediatric, Glioma, Ependymoma Trial in Seattle (EGFR806-specific chimeric antigen receptor (CAR) T cell)

Active, not recruiting
  • Central Nervous System Tumor, Pediatric
  • +8 more
  • EGFR806-specific chimeric antigen receptor (CAR) T cell
  • Seattle, Washington
    Seattle Children's Hospital
Jan 18, 2023

Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

Recruiting
  • Relapsed or Refractory CD19+ B-cell Lymphoma
  • +2 more
  • TBI-2001
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 26, 2023

Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,

Not yet recruiting
  • Kidney Transplant
  • +2 more
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

Lupus Erythematosus, Systemic Trial in Berlin (CC-97540, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Lupus Erythematosus, Systemic
  • Berlin, Germany
    Local Institution - 0025
May 22, 2023

Recurrent Glioblastoma, Refractory Glioblastoma Trial in Hangzhou, Huzhou, Ningbo (Temozolomide, B7-H3 CAR-T)

Recruiting
  • Recurrent Glioblastoma
  • Refractory Glioblastoma
  • Hangzhou, Zhejiang, China
  • +2 more
Dec 25, 2022

Gastric Cancer, Colon Cancer, Rectal Cancer Trial in Wuhu (CEA-targeted CAR-T cells)

Recruiting
  • Gastric Cancer
  • +7 more
  • CEA-targeted CAR-T cells
  • Wuhu, Anhui, China
    The First Affiliated Hospital of Wannan Medical College
Nov 9, 2023

T-cell Non-Hodgkin's Lymphoma Trial (CD147- CAR T cells)

Not yet recruiting
  • T-cell Non-Hodgkin's Lymphoma
  • CD147- CAR T cells
  • (no location specified)
Aug 1, 2022

Study of Participants Who ReceivedAllogeneic CAR T-Cell Product

Recruiting
  • Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical Study
    • Culver City, California
      Science 37, Inc.
    Apr 10, 2023

    Advanced Sarcoma Trial (NKG2D-CAR memory T cell)

    Not yet recruiting
    • Advanced Sarcoma
    • NKG2D-CAR memory T cell
    • (no location specified)
    Oct 17, 2023

    DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,

    Not yet recruiting
    • DLBCL - Diffuse Large B Cell Lymphoma
    • +6 more
    • Bridging radiation therapy
    • +2 more
    • (no location specified)
    Jan 4, 2023

    B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma Trial in Stanford (Fludarabine, Cyclophosphamide, Autologous

    Suspended
    • B Cell Lymphoma
    • +2 more
    • Stanford, California
      Stanford Medical Center
    Sep 8, 2022

    B-Cell Lymphoma, B Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma Trial in Pittsburgh (Chimeric Antigen Receptor

    Recruiting
    • B-Cell Lymphoma
    • +8 more
    • Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
    • Pittsburgh, Pennsylvania
      AHN Cancer Institute - West Penn Hospital
    Aug 10, 2022

    CNS Tumor, Pediatric, Glioma, Ependymoma Trial in Seattle (HER2-specific chimeric antigen receptor (CAR) T cell)

    Recruiting
    • Central Nervous System Tumor, Pediatric
    • +8 more
    • HER2-specific chimeric antigen receptor (CAR) T cell
    • Seattle, Washington
      Seattle Children's Hospital
    Dec 14, 2022

    Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,

    Recruiting
    • Refractory Multiple Myeloma
    • Relapsed Multiple Myeloma
    • Manufactured Anti-BCMA CAR-T cells
    • +2 more
    • San Francisco, California
      University of California, San Francisco
    Jan 6, 2023